Disclosure statement
S. Suissa has participated in advisory boards, as speaker, or received funding from AstraZeneca, Boehringer Ingelheim and Novartis. G. Sotgiu has no conflict of interest to declare. V. Brusasco received research funds from Novartis and fees for speaking at meetings from Novartis, Menarini, AstraZeneca, and Lusofarmaco.